Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market Report 2026

Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market Report 2026 Market Overview

• Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market Report 2026 market size has reached to $1.49 billion in 2025 • Expected to grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 10.7% • Growth Driver: Rising Infectious Disease Detection Fueling The Growth Of The Market Due To Increasing Adoption Of Advanced Molecular Diagnostic Technologies • Market Trend: Strategic Partnerships Enhance Automation And RNA Biomarker Detection In RNA In Situ Hybridization Workflows • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market?

A ribonucleic acid (RNA) in situ hybridization (ISH) is a molecular technique used to detect and visualize specific RNA sequences within cells or tissue samples. It enables researchers and clinicians to identify the location and expression patterns of target RNA molecules while preserving the structural context of the sample. A ribonucleic acid (RNA) in situ hybridization (ISH) uses labeled complementary probes that bind to specific RNA targets for microscopic analysis. The main product types of ribonucleic acid (RNA) in situ hybridization (ISH) include probes, kits and reagents, instruments, and services. Probes refer to labeled nucleic acid sequences designed to detect and bind specific RNA targets within cells or tissue samples. These products use technologies such as fluorescence in situ hybridization, chromogenic in situ hybridization, and ribonucleic acid scope. The key applications of diagnostic applications, cancer research, infectious diseases, neuroscience, developmental biology, and gene expression studies, while the end-users academic and research institutes, pharmaceutical and biotechnology companies, and clinical laboratories.

What Is The Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market Growth Forecast?

The ribonucleic acid (RNA) in situ hybridization (ish) market size is expected to see rapid growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to rising demand for precision oncology diagnostics, increasing adoption of spatial transcriptomics technologies, expansion of personalized medicine applications, growth in automated laboratory workflows, increasing investment in advanced genomic research infrastructure. Major trends in the forecast period include AI assisted spatial transcriptomics image analysis improving rna signal interpretation accuracy, ultra sensitive multiplex probe development enabling simultaneous multi target rna detection, automated slide hybridization platforms reducing manual error and improving throughput, advanced fluorescent imaging systems enabling high resolution intracellular rna mapping, single cell expression profiling innovations enhancing tissue level gene expression insights.

What Are The Drivers Of The Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market?

The rising infectious disease detection is expected to propel the growth of the ribonucleic acid (RNA) in situ hybridization (ISH) market going forward. Infectious disease detection refers to the increasing use of diagnostic techniques to identify viral, bacterial, and other pathogenic infections through molecular and laboratory-based analysis. Infectious disease detection is increasing due to the growing adoption of advanced molecular diagnostic technologies that enable faster and more accurate identification of pathogens. RNA in situ hybridization (ISH) supports infectious disease detection by identifying and localizing pathogen-specific RNA within tissue samples, enabling accurate visualization of infected cells while preserving tissue morphology. For instance, in May 2026, according to the UK Health Security Agency, a UK-based government agency, between 1 January and 25 May 2026, England recorded 630 laboratory-confirmed measles cases, representing an increase of 88 cases compared with the previous report published on 11 May 2026. Therefore, the rising infectious disease detection is driving the growth of the ribonucleic acid (RNA) in situ hybridization (ISH) industry. The increasing adoption of precision medicine is expected to propel the growth of the ribonucleic acid (RNA) in situ hybridization (ISH) market going forward. Precision medicine is a healthcare approach that customizes disease prevention, diagnosis, and treatment based on an individual’s genetic profile, biomarkers, and molecular characteristics. The adoption of precision medicine is increasing due to the growing prevalence of chronic diseases, particularly cancer, which requires highly targeted and personalized treatment strategies. RNA in situ hybridization (ISH) supports precision medicine by detecting and localizing specific RNA biomarkers within tissues, enabling molecular profiling that guides targeted therapies and improves patient-specific treatment outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, increasing adoption of precision medicine is driving the growth of the ribonucleic acid (RNA) in situ hybridization (ISH) industry.

Key Players In The Global Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market

Major companies operating in the ribonucleic acid (RNA) in situ hybridization (ish) market report are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies Inc., Charles River Laboratories, QIAGEN N.V., Bio-Techne Corporation, Akoya Biosciences Inc., Biocare Medical LLC, Biogenex Laboratories Inc., Empire Genomics LLC, BioChain Institute Inc., Boster Biological Technology Co. Ltd., AnaPath Services GmbH, Bio SB Inc., Enzo Biochem Inc.

Global Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market Trends and Insights

Major companies operating in the ribonucleic acid (RNA) in situ hybridization (ISH) market are focusing on adopting strategic partnerships to enhance workflow automation, improve visualization of RNA biomarkers, increase diagnostic accuracy, and support high-throughput molecular pathology analysis. Strategic partnerships are collaborative agreements between organizations to combine resources, expertise, or capabilities for achieving shared goals, expanding market presence, and driving mutual growth. For instance, in March 2026, Leica Biosystems Nussloch GmbH, a Germany-based medical technology manufacturer, partnered with Bio-Techne Corporation, a US-based life sciences company, to launch BOND-PRIME RNAscope Brown Detection to enhance automated chromogenic RNA in situ hybridization workflows, improve RNA biomarker visualization, and support high-throughput digital pathology and molecular diagnostics applications. Its key unique features include fully automated RNAscope in situ hybridization (ISH) workflow integration on the BOND-PRIME Staining Platform, enabling faster and standardized RNA biomarker detection with minimal manual intervention.

What Defines the Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market?

The ribonucleic acid (RNA) in situ hybridization (ISH) market consists of revenues earned by entities by providing services such as biomarker identification, molecular pathology testing, and tissue-based diagnostic research. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA) in situ hybridization (ISH) market also includes sales of assay controls, detection substrates, hybridization buffers, target-specific RNA probes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ribonucleic Acid (RNA) In Situ Hybridization (ISH) Market Report 2026?

The ribonucleic acid (rna) in situ hybridization (ish) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna) in situ hybridization (ish) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.